As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.
The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.
advertisement
There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Why doctors need education on FDA device approval process
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
